ANAVEX LIFE SCIENCES CORP.
AVXL · XNASCIK 1314052fmd_09BGMACS9C8GX0TPGWS4FPS49D制造业 · 生物制品（不含诊断试剂）模板: 标准
覆盖范围: 2003年10月01日 至 2026年6月30日，共 71 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 净利息收入 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 7 | 7 | 5 |
| 研发费用 | 7 | 11 | 13 | 22 | 25 | 33 | 38 | 44 | 42 | 38 |
| Taxes other than income taxes | – | – | 0 | 0 | 0 | 0 | 0 | – | – | – |
| 销售、一般及管理费用 | – | – | – | – | – | – | – | 12 | 11 | 14 |
| 薪酬与福利 | – | – | – | – | – | – | – | – | – | – |
| 营业费用合计 | 16 | 16 | 19 | 29 | (31) | 42 | 51 | 56 | 53 | 51 |
| 营业利润 | – | – | – | – | (31) | (42) | (51) | (56) | (53) | (51) |
| 利息费用 | – | – | – | – | – | – | – | – | – | – |
| 其他营业外收入（支出） | 1 | 2 | 2 | 3 | 5 | 4 | 3 | 8 | 10 | 5 |
| 税前利润 | (15) | (13) | (17) | (26) | (26) | (38) | (48) | (47) | (43) | (46) |
| 所得税费用 | – | – | – | – | – | – | – | – | – | – |
| 持续经营净利润 | – | – | – | – | – | – | – | – | – | – |
| 净利润 | (15) | (13) | (17) | (26) | (26) | (38) | (48) | (48) | (43) | (46) |